This week’s Medical Minute, discusses antibodies that play a role in the advancement of Myasthenia Gravis, a condition that affects points of communication between nerves and muscles.
Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.
A vaccine will only work if a lot of people can get immunized. State health officials are working furiously to design outreach and distribution plans, with little clarity from the federal government.
Here's irony: tobacco plants may be key in preventing COVID-19. Two companies are using the plants to produce proteins for a vaccine. One candidate vaccine is already in a clinical trial.
Pediatricians have been asking policy makers to include children in COVID-19 vaccine trials. Now, the FDA has given Pfizer approval to enroll adolescents as young as 12 years old.
From heat-related illness to mosquito-borne infections, physicians are seeing the effects of a warming planet in the exam room. There's a growing push to teach doctors-in-training how to respond.
In Libby, Mont., an estimated 1 in 10 have an asbestos-related illness, after decades of pollution from a now-shuttered mine. With lungs already scarred, many fear contracting the coronavirus.
Members of Congress and advocacy groups say Operation Warp Speed should release its contracts with vaccine makers after NPR reporting found the terms of many aren't public.
The use of an immune-system stimulant harvested from shark liver oil in the development of some coronavirus vaccines has animal conservationists pressing for alternatives.
Trump's physician said Trump could resume "public engagements" as soon as Saturday. But experts say that may be too soon, both for his own health and the safety of those around him.
Medical researchers have high hopes that the kind of treatment the president received could end up being an important element in the fight against the pandemic. But clinical trials continue.
Coughs, sore throats and runny noses are common in fall and winter, and they rarely signal dire disease. But with COVID-19 a threat this year and flu an annual hazard, here's what you need to know.
Large-scale safety and efficacy trials of experimental vaccines in tens of thousands of volunteers are underway. Answers about the trials are likely to come late this year.
